anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
SCOPE: Inflammatory bowel disease (IBD) is characterized by chronic inflammation in the gut, accompanied by impaired epithelial integrity, increased macrophage infiltration, and enhanced colon cancer risk.
METHODS AND RESULTS: Cannabidiol (CBD), a phytocannabinoid isolated from cannabis plants, is supplemented into mice diet, and its beneficial effects against dextran sulfate sodium (DSS)-induced experimental colitis is evaluated. Eight-week-old mice were fed a standard diet supplemented with or without CBD (200 mg kg-1 ) for 5 weeks. In the 4th week of dietary treatment, mice were subjected to 2.5% DSS induction for 7 days, followed by 7 days of recovery, to induce colitis. CBD supplementation reduced body weight loss, gross bleeding, fecal consistency, and disease activity index. In addition, CBD supplementation protected the colonic structure, promoted tissue recovery, and ameliorated macrophage infiltration in the colonic tissue, which was associated with the activation of cyclic AMP-protein kinase A, extracellular signal-regulated kinase ½, and AMP-activated protein kinase signaling pathways. CBD supplementation also suppressed NLRP3 inflammasome activation and related pro-inflammatory marker secretion. Consistently, CBD feeding reduced tight junction protein claudin2 and myosin light chain kinase in DSS-treated mice.
CONCLUSION: Dietary CBD protects against inflammation and colitis symptoms induced by DSS, providing an alternative approach to IBD management.
A method for preparing a vaccine for dental caries comprises the step of culturing a variant which is obtained by integrating a protein antigen (PAc)-expressing gene into the chromosomal gene of a Streptococcus mutans GS-5 strain to obtain the protein antigen, the protein antigen being produced on the surface of cells of oral Streptococcus mutans or it being extracellularly produced by the microorganism and having a molecular weight ranging from about 170,000 to 220,000. Streptococcus mutans GS-5 (K-3), in which a protein antigen-expressing gene is integrated into the chromosomal gene thereof, has an ability of producing the protein antigen on the surface of the cells or extracellularly. A preventive vaccine composition for dental caries for nasal drops comprises the protein antigen thus produced by the strain: Streptcoccus mutans, the vaccine being intranasally administered. The method makes it possible to enhance the yield of PAc and to simplify processes for purifying PAc. The vaccine composition makes it possible to internally easily absorb the protein antigen, PAc, in high efficiency and it also makes it possible to effectively increase the antibody titer observed after the administration thereof. 1
OBJECTIVE: To determine the extent to which various factors are associated with greater or lesser odds of reporting non-specific low back pain (NS-LBP) in field hockey.
METHODS: To meet the objective of the study, a cross-sectional study design was used with a purposive sampling strategy. A total of 194 responses (~18% of those accessible) from Premier and Division One players within the UK were received using a UK-based online survey. Data collected included information on NS-LBP, participant characteristics, injury history, training related factors, and work and personal factors. The overall and category-specific prevalence of NS-LBP was calculated. Univariable and multivariable logistic regression was used in conjunction with clinical value to identify associations.
RESULTS: The overall prevalence of NS-LBP was 44.0%, with this varying from 23.5 to 70.0% for categories with responses of "yes" and "no" to experiencing NS-LBP. A total of ten individual factors associated with a greater odds ratio (OR) of reporting NS-LBP (OR = 1.43-7.39) were identified in Premier and Division One players. Five individual factors were associated with reduced odds (OR = 0.11-0.60) of reporting NS-LBP. Seven factors (age, stature, playing position, playing internationally, performing a drag flick, low back stiffness/tightness and occupational factors) were deemed particularly pertinent to those working in field hockey given the magnitude of association and clinical value to clinicians.
CONCLUSIONS: Clinicians working in field hockey can consider the key risk factors identified in this study that are associated with NS-LBP when assessing injury risk, movement screening approaches, and overall athlete management.
Either of the following two regimens is recommended: 

  1. Leucovorin calcium for injection is administered at 200 mg/m2 by slow intravenous injection over a minimum of 3 minutes, followed by 5-fluorouracil at 370 mg/m2 by intravenous injection. 
  2. Leucovorin calcium for injection is administered at 20 mg/m2 by intravenous injection followed by 5-fluorouracil at 425 mg/m2 by intravenous injection. 



5-Fluorouracil and leucovorin should be administered separately to avoid the formation of a precipitate. 

Treatment is repeated daily for five days. This five-day treatment course may be repeated at 4 week (28-day) intervals, for 2 courses and then repeated at 4 to 5 week (28 to 35 day) intervals provided that the patient has completely recovered from the toxic effects of the prior treatment course. 

In subsequent treatment courses, the dosage of 5-fluorouracil should be adjusted based on patient tolerance of the prior treatment course. The daily dosage of 5-fluorouracil should be reduced by 20% for patients who experienced moderate hematologic or gastrointestinal toxicity in the prior treatment course, and by 30% for patients who experienced severe toxicity (see PRECAUTIONS: Laboratory Tests). For patients who experienced no toxicity in the prior treatment course, 5-fluorouracil dosages may be increased by 10%. Leucovorin calcium for injection dosages are not adjusted for toxicity.
PROBLEM TO BE SOLVED: To obtain a herbal preparation having synergistic antibacterial activity for oral hygiene, by including herbal extracts and an essential oil. SOLUTION: This preparation is obtained by including (A) herbal extracts/ plant material such as tincture and (B) an essential oil having an antibacterial activity. The tincture is preferably a mixture of plantago, Hypericum erectum, Echinaceae angustifoliae radix, and propolis. The essential oil is preferably selected from cinnamon oil, tea plant oil, citronella oil, and so on. The respective contents of the active ingredients of the preparation are as follows: herbal extracts, 1-10 wt.%; cinnamon oil, 0.1-5 wt.%; and citronella oil, 0.2-5 wt.%. This preparation is effective for the treatment of skin bacterial infectious diseases such as impetigo, folliculitis, acne, and furunculosis, and bacterial infectious diseases in other body tissue.  It is also effective for the treatment of bacterial infectious diseases in mucous membranes such as of vaginal tissue, anal tissue, oral cavity tissue, and other orifice tissues, and ocular tissue. Fungal, viral, and parasitical infectious diseases can also be treated with this preparation.
PURPOSE: A recombinant expression vector containing a fusion gene having cholera toxin B subunit(sCTB) gene and an neutralizing epitope(sCOE) gene of porcine epidemic diarrhea virus is provided to effectively and simply prevent porcine epidemic diarrhea virus. CONSTITUTION: A recombinant plant expression vector contains a fusion gene of cholera toxin B subunit(sCTB) gene and a neutralizing epitope(sCOE) of porcine epidemic diarrhea virus. The sCTB gene has a base of sequence number 1. The sCOE gene has a base of sequence number 2. A vector contains a fusion gene having Kosak sequence(GCCACC), sCTB gene having a base of sequence number 1, GPGP coding sequence, sCOE gene having a base of sequence number 2, and ER retention signal(SEKDEL) coding sequence. The vector is pMYV514 vector. A vaccine composition for porcine epidemic diarrhea virus contains recombinant Sctb-sCOE fusion protein.
PURPOSE:The titled substance, obtained by treating an intestinal mucous membrane of a warm-blooded vertebrate with a salt solution containing no calcium, centrifugung the resultant homogenate, and dialyzing the resultant supernatant liquid, and useful as a hepatic functin promotor, etc. CONSTITUTION:The intestinal mucous membrane of a warm-blooded vertebrate, e.g. a rat, mouse or domestic fowl, is collected, and treated with a salt solution, e.g. Tyrode's solution, containing substantially no calcium to give a homogenate, which is then centrifuged. The resultant supernatant liquid after the centrifugation is heated at 60-100 deg.C and dialyzed to afford the aimed substance. The resultant substance is nondialytic and eluted by the chromatography with ''ConA- Sepharose '' without exhibiting the property of polysaccharide or glycoprotein. The compound has multiplication promoting action on the hepatic cell, and the hepatic parenchymal cell can be cultivated by adding the substance even to a culture medium containing no blood serum. The substance is expected to be applied as a hepatic function promotor, etc.
The study lasted 30 days for each participant. The patients enrolled were randomly divided into the experimental group and the control group, all under routine rehabilitation therapy.
The AECOPD cohort will be hospitalized for an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) with respiratory failure requiring invasive or non-invasive mechanical ventilation. We will be following patients from admission through to discharge, and during a follow-up visit (\~2 months from discharge). During the follow-up visit we will be administering 60mg of methylprednisolone once to study possible steroid resistance.
Sinensetin is a product isolated from Orthosiphon aristatus, and its antitumor activities have been well established. This study focused on the role and mechanism of sinensetin in lung adenocarcinoma (LUAD). LUAD cells were treated with various concentrations of sinensetin. The proliferation, migration, invasion, and angiogenesis of LUAD cells were detected using colony formation, transwell, and tube formation assays, respectively. The protein levels of VEGF-A, VEGFR-2, and phosphorylated AKT (ser473) were measured by western blotting. The targeted relationship between VEGF-A and miR-374c-5p was verified by luciferase reporter assay. BALB/c nude mice inoculated with A549 cells were treated with sinensetin (40 mg/kg/day) by gavage for 21 days to investigate the effect of sinensetin on tumor growth and angiogenesis in vivo. We found that sinensetin reduced proliferation, migration, invasion, angiogenesis, and cancer stem characteristics of LUAD cells. Sinensetin also suppressed LUAD tumor growth and angiogenesis in vivo. Sinensetin downregulated VEGF-A expression in LUAD cells by enhancing miR-374c-5p expression. MiR-374c-5p inhibited the VEGF-A/VEGFR-2/AKT pathway in LUAD cells. The antitumor effect of sinensetin was reversed by overexpression of VEGF-A or inhibition of miR-374c-5p. Overall, sinensetin upregulates miR-374c-5p to inhibit the VEGF-A/VEGFR-2/AKT pathway, thereby exerting antitumor effect on LUAD.
* OXAYDO should be prescribed only by healthcare professionals who are knowledgeable about the use of opioids and how to mitigate the associated risks.
  * Use the lowest effective dosage for the shortest duration of time consistent with individual patient treatment goals [see Warnings and Precautions (5)]. Because the risk of overdose increases as opioid doses increase, reserve titration to higher doses of OXAYDO for patients in whom lower doses are insufficiently effective and in whom the expected benefits of using a higher dose opioid clearly outweigh the substantial risks.
  * Many acute pain conditions (e.g., the pain that occurs with a number of surgical procedures or acute musculoskeletal injuries) require no more than a few days of an opioid analgesic. Clinical guidelines on opioid prescribing for some acute pain conditions are available.
  * There is variability in the opioid analgesic dose and duration needed to adequately manage pain due both to the cause of pain and to individual patient factors. Initiate the dosing regimen for each patient individually, taking into account the patient’s underlying cause and severity of pain, prior analgesic treatment and response, and risk factors for addiction, abuse, and misuse [see Warnings and Precautions (5.1)].
  * Respiratory depression can occur at any time during opioid therapy, especially when initiating and following dosage increases with OXAYDO. Consider this risk when selecting an initial dose and when making dose adjustments [see Warnings and Precautions (5.2)].
  * OXAYDO must be swallowed whole. Take each tablet with enough water to ensure complete swallowing immediately after placing in the mouth.
  * OXAYDO is not amenable to crushing and dissolution. Do not administer OXAYDO via nasogastric, gastric or other feeding tubes as it may cause obstruction of feeding tubes.
ASO eye drops are used through the local administration. Dosage form: eye drop solution. Dose:20uL. Frequency of administration: 3 times per day.
The invention refers to 3-aminopyrroles according to the general formula I, (which are mainly new), the preparation procedure of aminopyrrole and its application in medicaments or medicinal substances. The invention also refers to its anticonvulsive or analgetic preparations. Di-substituted or mono-substituted amino-groups are given as 3-aminosubstituents. The invention is mainly focused on the development of new, on a central nervous system (CNS)-active 3-aminopyrroles, particularly those with anticonvulsive or analgetic properties, as well as their preparation procedure and their application as medicinal substances. According to the invention, the synthesis is done by cyclisation of open chain predecessors, e.g. aminoacrylic acid derivatives, or by modifying the pyrroles of formula 1. (I)
The invention relates to a traditional Chinese medicine compound composition taking taxus chinensis as a monarch drug and application thereof. The invention provides a traditional Chinese medicine compound composition taking taxus chinensis as a monarch drug and application thereof. The invention relates to a Chinese medicinal compound composition taking Chinese yew as a monarch drug, which consists of Chinese yew, glossy privet fruit, lucid ganoderma, barbed skullcap herb and dandelion. The traditional Chinese medicine compound composition is applied to the preparation of antitumor drugs. The serum containing the medicine with different concentrations has good proliferation inhibition effect on tumor cells and has concentration dependence. In-vivo experiments, the traditional Chinese medicine compound disclosed by the invention has a good growth inhibition effect on a tumor cell nude mouse transplantation tumor model, and the tumor inhibition rate of a high-dose group of the traditional Chinese medicine compound is 50.8%. The invention is applied to the field of anti-tumor.
UNLABELLED: This study analyzes the epidemiology of pediatric drowning in Israel from 2010 to 2022, focusing on differences across age groups, sex, and regions. We conducted a retrospective cohort study using data from the Ministry of Health's administrative databases, covering all children aged 0-17 years who were seen in the emergency department, discharged after hospitalization, or died at the scene due to drowning, excluding cases of intentional harm or suicide. The primary outcome was the annual drowning rate per 100,000 children, categorized by age, sex, and region, along with hospitalization duration, intensive care unit admissions, and mortality rates. A total of 2101 drowning incidents were identified, with 9% resulting in death. Higher drowning rates were found in younger children (1-4 years) and teenagers (15-17 years), with notable differences by sex. Drowning rates were higher in coastal regions and more frequent during winter and spring. An increase in drowning rates was observed over the last 3 years of the study (2020-2022). Children hospitalized for more than 3 days had significantly higher mortality rates, both in general wards and intensive care units.
CONCLUSIONS: Pediatric drowning is a persistent public health concern in Israel, with distinct seasonal, regional, age-specific, and sex-specific patterns in incidence and mortality. This study underscores the need for a comprehensive prevention strategy that includes year-round public education, environmental safety measures, and targeted interventions for high-risk groups to reduce drowning incidents and fatalities among children effectively.
WHAT IS KNOWN: • Pediatric drowning represents a significant public health challenge globally, with varying rates. • In Israel, pediatric drowning is the second leading cause of death from all injury-related deaths. Thus far, the measures and interventions to reduce fatalities were not proven effective enough.
WHAT IS NEW: • Pediatric drowning in Israel, with a 9% mortality rate, revealed a biphasic rate varied by sex and is higher in coastal regions and during winter and spring. • There was a notable increase in drowning incidents during the last 3 years of the study period (2020-2022), coinciding with the COVID-19 pandemic.
PURPOSE:To provide the titled composition having low irritancy to the nasal mucous membrane and little ill odor, and composed of a lower alkyl ether of cellulose, beclomethasone dipropionate and an odorless solid organic acid as a stabilizer. CONSTITUTION:A stabilized powdery drug composition for the application to the nasal mucous membrane, is prepared by compounding (A) a lower alkyl ether of cellulose (e.g. hydroxypropylcellulose) preferably having a water-content of 3- 9wt%, (B) beclomethasone dipropionate which is a steroidal anti-inflammatory agent, and (C) an odorless organic acid solid at normal temperature (e.g. stearic acid, palmitic acid, etc.) as a stabilizer. The particles having an effective particle diameter of about 20-250mu acount for preferably >=90wt% of the composition. Dose for application: 5-200mg per dose. It is suitable for the treatment of allergic rhinitis, vasomotor rhinitis, etc.
The virtual single-energy imaging of energy spectrum CT combined with the metal artifact reduction technology MARS Multi Artifact Reduction System\] can effectively reduce the interference of metal artifacts. This is because MAR technology corrects the image through an iterative algorithm, improves the spatial resolution, and restores the details of the adjacent tissue of the metal object. Virtual single-energy imaging technology can effectively reduce hardening artifacts. The two are used in combination to achieve the purpose of reducing metal artifacts. There have been articles about virtual single energy combined with MAR technology to reduce metal artifacts. However, the current researches mostly focus on the comparison of virtual single energy combined with MAR technology and conventional CT examination and virtual single energy imaging. There are few evaluations on the severity of metal artifacts after spinal surgery. According to different surgical methods, metal The difference in the number of implants will result in different artifact reduction effects. Secondly, the current research on the suitable KeV of virtual single energy combined with MAR technology to reduce metal artifacts is less discussed and reported.
After randomization, vasopressin will be initiated and titrated up to 0.04U/min to maintain the target mean arterial pressure (MAP). Concurrently, norepinephrine will be reduced, with the goal of using the maximum dose of vasopressin and minimizing or eliminating the use of norepinephrine, while still maintaining the target MAP.
A total of 10 participants at week 0 and week 8 will have Tabasco® Sauce present in 2-3 drops of water applied to their skin and covered in a light dressing. Tabasco® Sauce is an ideal placebo as the sensation to the skin is similar to a hookworm. All participants will undergo interventions of Gluten free diet, Gluten micro-challenge, Inadvertent gluten challenge and Moderate gluten challenge.
BACKGROUND: A venous aneurysm (VA) is a focal dilatation of a nonvariceal vein (diameter increased by at least 1.5 times compared to the adjacent upstream or downstream venous segment), which carries a risk of venous thromboembolism (VTE) when located in the deep veins of the lower limbs but also when it affects the veins above the muscle fascia.
CASE: We report the case of a 40-year-old woman who presented with a painful and disabling mass-like lesion of the upper third of the right calf. A Doppler ultrasound (DUS) examination revealed a small saphenous vein (SSV) dilated at the saphenopopliteal junction (SPJ) and thrombosed along its entire length. Anticoagulant treatment was initiated but although the thrombosis regressed on DUS, the functional impotence and the persistence of pain prompted a stripping of the SSV. Histology allowed the diagnosis of SSV's primary aneurysm.
DISCUSSION: Dilated segments of the saphenous vein are not always varicose veins (VVs). True VAs can develop on veins located above the muscular fascia and, like deep VAs, may trigger VTE. Small saphenous vein aneurysms have seldom been reported, and only a few clinical observations have described the thrombosis of a SSV aneurysm. Any mass in the popliteal fossa or upper part of the calf should be examined by DUS to look for an SSV aneurysm. Excision of the saphenous vein with junctional ligation is advised if thrombosis is present at the time of diagnosis.
The invention relates to a novel tilapia mossambica virus and application thereof. The present invention relates to isolated luo lake virus or TiLV, and isolated nucleic acid sequences and polypeptides thereof. The invention also relates to probes and primers, and to antibodies to antigens from TiLV, and the use of these reagents for detecting the presence or absence of TiLV in an animal. The invention also relates to irnas that target the nucleic acid sequence of TiLV. The invention also relates to immunogenic compositions, including antibodies and vaccines, for inducing an immune response against TiLV in an animal. The invention also relates to genetic constructs and cells comprising TiLV and isolated nucleic acid sequences and polypeptides thereof for the development of prophylactic and therapeutic agents.
The research will be developed in the hemodialysis unit of the Santa Clara hospital of Santa Casa de Misericórdia de Porto Alegre. After the selection of patients for eligibility criteria they will be randomized into IMTG or control group. First all patients will be evaluated, and subsequently the patients in the IMTG will be trained six times per week (three times at hemodialysis unit and three times at home) for five weeks using a linear pressure load device (POWERbreathe Plus Light Resistance@, England). The sessions will take place in the first hour of dialysis and the training protocol will consist of five series with 10 repetitions, each serie with a two-minute interval or according to the patient´s feedback, using the Borg modified scale. The overload will be adjusted weekly, beginning with 50% of maximum inspiratory pressure and increasing until 70% along the protocol period. At the end of follow-up, both groups will be evaluated in order to compare.